表皮生长因子受体（EGFR）突变型肺癌中基于序贯血浆游离DNA指导的两种EGFR酪氨酸激酶抑制剂的亚克隆治疗 - Suppr

Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer.

作者信息

Peled Nir, Roisman Laila C, Miron Benjamin, Pfeffer Raphael, Lanman Richard B, Ilouze Maya, Dvir Addie, Soussan-Gutman Lior, Barlesi Fabrice, Tarcic Gabi, Edelheit Oded, Gandara David, Elkabetz Yehiel

机构信息

Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.

出版信息

J Thorac Oncol. 2017 Jul;12(7):e81-e84. doi: 10.1016/j.jtho.2017.02.023. Epub 2017 Mar 7.

DOI:10.1016/j.jtho.2017.02.023

PMID:28286242

Abstract

摘要

相似文献

Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer.

J Thorac Oncol. 2017 Jul;12(7):e81-e84. doi: 10.1016/j.jtho.2017.02.023. Epub 2017 Mar 7.

Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.

Lung Cancer. 2017 Apr;106:138-144. doi: 10.1016/j.lungcan.2017.02.001. Epub 2017 Feb 4.

Direct quantification of EGFR variant allele frequency in cell-free DNA using a microfluidic-free digital droplet PCR assay.

Methods Cell Biol. 2018;148:119-131. doi: 10.1016/bs.mcb.2018.10.002. Epub 2018 Nov 1.

Comparison of five cell-free DNA isolation methods to detect the EGFR T790M mutation in plasma samples of patients with lung cancer.

Clin Chem Lab Med. 2018 Aug 28;56(9):e243-e246. doi: 10.1515/cclm-2017-0967.

EGFR and KRAS Mutations in Triple-Mutated Lung Cancer.

J Thorac Oncol. 2017 Jul;12(7):e92-e93. doi: 10.1016/j.jtho.2017.02.022.

A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.

Clin Cancer Res. 2016 Dec 15;22(24):6010-6020. doi: 10.1158/1078-0432.CCR-16-0909. Epub 2016 Jun 8.

CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients.

Tumour Biol. 2015 Aug;36(8):5943-51. doi: 10.1007/s13277-015-3269-6. Epub 2015 Mar 3.

Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.

Oncotarget. 2016 Jul 12;7(28):44583-44595. doi: 10.18632/oncotarget.10069.

EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1305-1310. doi: 10.1007/s00280-016-3155-y. Epub 2016 Oct 21.

Genetic profiling of cell-free DNA from cerebrospinal fluid: opening the barrier to leptomeningeal metastasis in EGFR-mutant NSCLC.

Ann Oncol. 2018 Apr 1;29(4):789-791. doi: 10.1093/annonc/mdy053.

引用本文的文献

Characterization of Patients with Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France.

Onco Targets Ther. 2024 May 29;17:439-448. doi: 10.2147/OTT.S448909. eCollection 2024.

Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.

Front Immunol. 2024 Apr 9;15:1366260. doi: 10.3389/fimmu.2024.1366260. eCollection 2024.

Synthesis and initial evaluation of olmutinib derivatives as prospective imaging probe for non-small cell lung cancer.

Bioimpacts. 2024;14(1):27774. doi: 10.34172/bi.2023.27774. Epub 2023 Aug 19.

A Novel Dual-labeled Peptide for Multimodal Imaging of EGFR with L858R Mutation.

Curr Radiopharm. 2024;17(2):174-183. doi: 10.2174/0118744710249198231002055810.

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial.

BMC Cancer. 2023 Jan 3;23(1):6. doi: 10.1186/s12885-022-10467-w.

NSCLC patients with rare Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report.

Front Oncol. 2022 Nov 24;12:1054593. doi: 10.3389/fonc.2022.1054593. eCollection 2022.

Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance.

Front Oncol. 2022 Apr 7;12:853501. doi: 10.3389/fonc.2022.853501. eCollection 2022.

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies.

ESMO Open. 2021 Dec;6(6):100280. doi: 10.1016/j.esmoop.2021.100280. Epub 2021 Oct 9.

Afatinib as a Potential Therapeutic Option for Patients With NSCLC With G724S.

JTO Clin Res Rep. 2021 May 24;2(7):100193. doi: 10.1016/j.jtocrr.2021.100193. eCollection 2021 Jul.

Clinical and Pathologic Complete Response to Gefitinib in a Patient with SqCLC Harboring EGFR p.E746_S752delinsV Mutation.

Onco Targets Ther. 2021 Sep 15;14:4805-4808. doi: 10.2147/OTT.S328839. eCollection 2021.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献